Recent Updates — COR
Cencora has entered into a definitive agreement to acquire all outstanding equity interests in American Oncology Network (AON) that it does not already own, valuing the physician-led oncology network at an enterprise value of $2.4 billion. The transaction consists of approximately $2.3 billion payable at closing and contingent value rights of up to $100 million. Cencora currently holds about 4% of AON; assuming a 25% equity rollover by certain stockholders, the company expects to pay roughly $1.7 billion in cash to increase its ownership stake to 75%. The deal is expected to be accretive to adjusted diluted EPS in the second year post-closing and remains subject to customary closing conditions, including regulatory clearances and AON shareholder approval. Cencora operates as a leading global pharmaceutical solutions organization providing supply chain and healthcare services.
Cencora, Inc. appointed Robert E. Sanchez as an independent director to its Board of Directors, effective October 1, 2026. The Board increased in size from ten to eleven members to accommodate the appointment. Mr. Sanchez serves as Executive Chair of Ryder System, Inc., and previously held roles including CEO and CFO at Ryder. He also sits on the board of Texas Instruments and is a trustee of the University of Miami. Cencora operates in the pharmaceutical distribution and supply chain industry.
On August 13, 2026, Lorence H. Kim, M.D., resigned from the Board of Directors effective immediately following a quarterly board meeting. His departure is linked to his appointment as Chief Financial Officer at Commonwealth Fusion Systems, Inc., requiring additional professional commitment. Dr. Kim confirmed that his resignation stems solely from these new obligations and involves no disagreements with Cencora regarding operations or policies. The company acknowledged his dedicated service. Cencora operates in the pharmaceutical distribution industry.
Cencora disclosed that beginning July 1, 2026, certain Walgreens volume previously serviced separately from the prime vendor agreement began moving outside the Company. The company clarified that this transition was fully anticipated in its August 5, 2026 commentary regarding fourth-quarter expectations for its U.S. Healthcare Solutions segment and reaffirmed its adjusted diluted EPS guidance range of $17.75 to $17.95 for fiscal year 2026. Cencora operates as a wholesale distributor of pharmaceuticals and healthcare products.
On July 31, 2026, Cencora, Inc. amended its Multi-Currency Revolving Credit Facility to increase aggregate commitments from $5.5 billion to $7.0 billion and extend the maturity date to July 2031. The company also reduced its Receivables Securitization Facility size from $1.5 billion to $1.0 billion while increasing the accordion feature capacity to $1.0 billion. These changes align financial covenants across facilities and provide additional liquidity for ongoing business needs. Cencora operates in the pharmaceutical distribution industry, providing supply chain management services to healthcare providers.
Cencora reported fiscal third quarter revenue of $84.8 billion, a 5.1 percent year-over-year increase, with diluted earnings per share rising to $3.94 and adjusted diluted EPS reaching $4.48. The company raised its full-year adjusted diluted EPS guidance range to $17.75–$17.95 from the previous $17.70–$17.90. Additionally, Cencora repurchased $1 billion of shares during the quarter and declared a quarterly cash dividend of $0.60 per share payable on August 31, 2026, to record holders as of August 14, 2026. The company operates in the pharmaceutical distribution and healthcare solutions industry.